Vijaypd Ceutical IPO presents a fresh issue fixed at ₹35 per share with a lot size of 4,000 shares, opening from September 29 to October 1, 2025. The company has over 50 years of experience as a pharmaceutical and consumer goods distributor, offering a wide range of products like medicines, wellness items, FMCG goods, and diagnostic kits. Investors can consider Vijaypd Ceutical IPO for long-term growth exposure in a sector driven by steady demand and healthcare expansion.
₹00
₹35
₹35.00
Expert Opinions
Market sentiment for Vijaypd Ceutical IPO is generally positive, given the company’s remarkable financial growth and expansion of its distribution network in Maharashtra. The company’s strengths include a vast portfolio of pharmaceutical and FMCG products, a network spanning over 2,100 pharmacies and clinics, experienced management, and robust supply chain operations. However, risks such as geographic concentration, quality control, and exposure to operational or industry-specific downturns remain relevant.
In the valuation analysis for financial year 2025, the Vijaypd Ceutical IPO delivers a Return on Equity (ROE) of 28.91%, Return on Capital Employed (ROCE) of 17.30%, and a Net Asset Value (NAV) of ₹25.78, reflecting moderate profitability and efficient asset utilization. Over the long term, investors may find promise in its ambitious expansion plans and steady healthcare demand, though careful attention to regional exposure and industry volatility is necessary.
Investor Considerations
Vijaypd Ceutical IPO reflects a company with surging revenue, which almost doubled to ₹107.59 crore in FY 2025, and a robust presence across over 2,100 healthcare outlets in four districts. Fundamentals are supported by a diverse product mix spanning pharmaceuticals, wellness, diagnostics, and FMCG goods, alongside a well-established supply chain and strategic expansion into API manufacturing. The sector outlook remains positive on the back of healthcare demand and government initiatives to boost pharmaceutical infrastructure.
In the financial year 2025, Vijaypd Ceutical IPO posts a Return on Net Worth (RONW) of 14.91%, PAT margin of 4.49%, and Debt/Equity ratio of 0.68, indicating moderate profitability and manageable leverage. Key risks include regional concentration, quality control, and dependency on sector dynamics. Long-term investors may benefit from ongoing sector growth, while short-term participants should account for market volatility and execution risks.
| Date | GMP | Trend |
|---|---|---|
| 06 Oct 2025 11.39 | ₹00 | --- |
| 04 Oct 2025 11.24 | ₹00 | --- |
| 03 Oct 2025 12.07 | ₹00 | --- |
| 01 Oct 2025 12.44 | ₹00 | --- |
| 29 Sep 2025 13.31 | ₹00 | --- |
FAQs
The Grey Market Premium showed strong accuracy in predicting Vijaypd Ceutical IPO’s listing performance. With a final GMP of ₹0, it projected no premium or discount over the issue price of ₹35. The stock listed exactly at ₹35, delivering 0% gain. This resulted in no prediction error (0%), where the GMP correctly signaled a flat listing and perfectly aligned with the actual outcome, reflecting strong reliability in this case.
Vijaypd Ceutical IPO Current GMP is ₹00.
Vijaypd Ceutical IPO Expected Returns is 0.00%.
Vijaypd Ceutical IPO estimated listing price is ₹35.